In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read More
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read More
In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreIn a nutshell This phase 2 trial will investigate the effect of vopratelimab (JTX-2011) and ipilimumab (Yervoy) in non-small cell lung cancer (NSCLC). The main outcome will be the overall response (OR). This trial is recruiting at multiple locations in the US. The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreIn a nutshell This trial aims to investigate the safety and effectiveness of durvalumab (Imfinzi) combined with chemotherapy and radiation in patients with advanced lung tumors. The main outcome that will be measured is if there are any side effects and survival without signs of disease. The details Duravalumab is an anti-cancer...
Read More
In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...
Read More
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of a new immunotherapy in the treatment of patients with advanced colorectal cancer (CRC). The main outcome to be measured will be tumor response to the treatment. This study is being conducted in Texas, USA. The details CRC is the third most common cancer worldwide. The 5-year...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse). This trial is recruiting in multiple locations in New York and New Jersey, US. The details...
Read More
